216 related articles for article (PubMed ID: 14506660)
1. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy.
Viola GM; Zu Y; Baker KR; Aslam S
Med Oncol; 2011 Dec; 28(4):1604-8. PubMed ID: 20680523
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.
Mensen A; Na IK; Häfer R; Meerbach A; Schlecht M; Pietschmann ML; Gruhn B
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1971-80. PubMed ID: 24962343
[TBL] [Abstract][Full Text] [Related]
4. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.
Mehra V; Rhone E; Widya S; Zuckerman M; Potter V; Raj K; Kulasekararaj A; McLornan D; de Lavallade H; Benson-Quarm N; Lim C; Ware S; Sudhanva M; Malik O; Nicholas R; Muraro PA; Marsh J; Mufti GJ; Silber E; Pagliuca A; Kazmi MA
Clin Infect Dis; 2019 Oct; 69(10):1757-1763. PubMed ID: 30980715
[TBL] [Abstract][Full Text] [Related]
7. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
9. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
10. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
Brunstein CG; Weisdorf DJ; DeFor T; Barker JN; Tolar J; van Burik JA; Wagner JE
Blood; 2006 Oct; 108(8):2874-80. PubMed ID: 16804113
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Uchida N; Maeda T; Mori T; Kanda Y; Kondo T; Shiratori S; Miyakoshi S; Ishiyama K; Ikegame K; Matsuhashi Y; Tanaka J; Ichinohe T; Atsuta Y; Ogata M; Suzuki R
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1441-1449. PubMed ID: 30794929
[TBL] [Abstract][Full Text] [Related]
12. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
Burt RK; Traynor AE; Pope R; Schroeder J; Cohen B; Karlin KH; Lobeck L; Goolsby C; Rowlings P; Davis FA; Stefoski D; Terry C; Keever-Taylor C; Rosen S; Vesole D; Fishman M; Brush M; Mujias S; Villa M; Burns WH
Blood; 1998 Nov; 92(10):3505-14. PubMed ID: 9808541
[TBL] [Abstract][Full Text] [Related]
13. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Nash RA; Bowen JD; McSweeney PA; Pavletic SZ; Maravilla KR; Park MS; Storek J; Sullivan KM; Al-Omaishi J; Corboy JR; DiPersio J; Georges GE; Gooley TA; Holmberg LA; LeMaistre CF; Ryan K; Openshaw H; Sunderhaus J; Storb R; Zunt J; Kraft GH
Blood; 2003 Oct; 102(7):2364-72. PubMed ID: 12763935
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.
Calistri E; Tiribelli M; Battista M; Michelutti A; Corbellino M; Viale P; Fanin R; Damiani D
Am J Hematol; 2006 May; 81(5):355-7. PubMed ID: 16628717
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
[TBL] [Abstract][Full Text] [Related]
17. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.
Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K
Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation.
Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
J Pediatr Hematol Oncol; 2005 Oct; 27(10):532-6. PubMed ID: 16217256
[TBL] [Abstract][Full Text] [Related]
20. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
